Workflow
Beijing Marathon to Global Runners: Welcome to a Golden Autumn Race in Beijing
Globenewswire· 2025-09-10 10:37
BEIJING, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Bank of China Beijing Marathon 2025 officially opened for global registration at 10:00 AM on September 10. Global participants can register on the Beijing Marathon website (https://en.beijing-marathon.com/) or the Bank of China website (https://www.boc.cn/en/). A Media Snippet accompanying this announcement is available by clicking on this link. The race will begin at 7:30 AM on November 2, with an expected 32,000 runners taking to the course for a golden au ...
Cre8 Enterprise Limited Explores Strategic Alliances with Japanese Financial Printing Firms
Globenewswire· 2025-09-10 10:30
Hong Kong, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Cre8 Enterprise Limited (Nasdaq: CRE) (“Cre8” or the “Company”), a Hong Kong-based integrated financial printing service provider, announced today that it is actively exploring strategic alliances with financial printing and compliance solution providers in Japan. These partnerships are intended to strengthen support for cross-border IPOs and dual listings, while enhancing the delivery of integrated solutions for multinational issuers. By leveraging local expert ...
Dundee Precious Metals Reports High-Grade Intercepts at Dumitru Potok of 131.6 metres grading 3.93% CuEq and 76 metres at 2.47% CuEq
Globenewswire· 2025-09-10 10:30
TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Dundee Precious Metals Inc. (TSX:DPM) (“DPM”) today reported high-grade copper-gold-silver intercepts from its ongoing Serbian exploration program, including the Dumitru Potok prospect. Results included an intercept of 131.6 metres grading 3.93% CuEq, comprised of 1.53% Cu, 2.41 g/t Au and 12 g/t Ag from 1,126 metres and 76 metres at 2.47% CuEq, comprised of 1.01% Cu, 1.43 g/t Au and 10.37 g/t Ag from 1,277 metres downhole at hole DPDD032. This represents one of t ...
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
Globenewswire· 2025-09-10 10:30
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (p<.0001) BXCL501 showed a similar reduction in agitation symptoms over both the duration of the trial and number of treated episodes, demonstrating continued effects and consistent benefit with repeat dosing of BXCL501 Based on the large ...
S&P Global Ratings affirmed Oma Savings Bank Plc's credit rating and changed outlook to negative
Globenewswire· 2025-09-10 10:25
OMA SAVINGS BANK PLC STOCK EXCHANGE RELEASE 10 SEPTEMBER 2025 AT 1.25 P.M. EET, OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE S&P Global Ratings affirmed Oma Savings Bank Plc's credit rating and changed outlook to negative On 10.9.2025 June 2025, S&P Global Ratings (S&P) has affirmed that the short-term and long-term issuer credit ratings of Oma Savings Bank Plc (OmaSp or the Company) remain unchanged and are BBB/A-2. At the same time, S&P has changed OmaSp's outlook from stable to nega ...
Man Group PLC : Form 8.3 - Deliveroo Plc - Amendment
Globenewswire· 2025-09-10 10:22
Amendment – Corrected date of dealing FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of of ...
FITUEYES Concludes a Successful Showcase at IFA Berlin 2025
Globenewswire· 2025-09-10 10:20
FITUEYES FITUEYES Concludes a Successful Showcase at IFA Berlin 2025 BERLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FITUEYES, the design-forward creator of iconic TV stands and audio-visual furniture, successfully wrapped up its participation at IFA Berlin 2025, marking a milestone in its mission to redefine home entertainment and lifestyle design. Over the five-day event, FITUEYES welcomed thousands of visitors, journalists, and global partners. Showcasing Design Without Boundaries Unlike traditional TV st ...
Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation
Globenewswire· 2025-09-10 10:00
Core Viewpoint - Greenwich LifeSciences, Inc. has received Fast Track designation from the FDA for its immunotherapy GLSI-100, aimed at preventing breast cancer recurrences in HLA-A*02 positive patients who have completed standard HER2/neu targeted therapy [1][2] Company Overview - Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy designed to prevent breast cancer recurrences in patients post-surgery [9][11] - The company is currently conducting a Phase III clinical trial named FLAMINGO-01, which evaluates the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients [7][11] Fast Track Designation - The Fast Track designation allows for more frequent communication between the FDA and the company, potentially leading to earlier drug approval and the ability to submit parts of the Biologic License Application (BLA) as they are completed [2][5] - The designation is granted to drugs that address serious conditions and fill unmet medical needs, with GLSI-100 showing potential to improve invasive breast cancer-free survival [2][4] Clinical Trial Details - FLAMINGO-01 is designed to include approximately 500 HLA-A*02 patients randomized to receive GLSI-100 or placebo, with an interim analysis planned after 14 events of invasive breast cancer [7] - The trial aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, providing 80% power if the annual event rate in placebo-treated subjects is 2.4% or greater [7] Previous Clinical Data - In a Phase IIb trial, GLSI-100 demonstrated an 80% or greater reduction in cancer recurrences over five years in HER2/neu 3+ patients, with no serious adverse events reported [6][10] - The immunotherapy was well tolerated, and booster injections every six months prolonged the immune response, indicating a strong safety profile [6][10]
RecycLiCo Strengthens Technical Expertise with the Addition of Mohammadali (Mo) Shahsavari as Materials Scientist and Process Engineer
Globenewswire· 2025-09-10 10:00
Core Insights - RecycLiCo Battery Materials Inc. has appointed Mohammadali (Mo) Shahsavari as Materials Scientist and Process Engineer to enhance its scientific and engineering capabilities [1][2] - The company aims to transition from a venture-stage battery recycler to a significant player in North America's critical minerals supply chain, focusing on energy security and global competitiveness [1][3] Company Overview - RecycLiCo specializes in critical minerals refining, utilizing advanced hydrometallurgical technologies to process mined ore and upcycle lithium-ion battery materials [4] - The company efficiently recovers battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, aligning with the demand for responsible supply chains [4] Personnel Background - Mr. Shahsavari has over seven years of technical experience in materials characterization, electrochemistry, corrosion, and hydrometallurgy, holding a Master of Applied Science in Materials Engineering [2] - His previous role as a Lab Process Engineer at BQE Water involved developing innovative processes for wastewater treatment and resource recovery [2] Strategic Positioning - RecycLiCo is positioning itself at the forefront of the strategic reconfiguration of critical minerals sourcing, recovery, refining, and reuse in North America [3] - The company is focused on scaling its technology for not only lithium-ion battery recycling but also for refining and recovering critical minerals from newly-mined ore, existing stockpiles, and industrial scrap [3]
MEDIA AVAILABILITY: Uniformed CN Police Officers Available for Media Interviews During See Tracks? Think Train® Week 2025
Globenewswire· 2025-09-10 10:00
Core Message - CN is launching its annual public awareness campaign, See Tracks? Think Train® Week, from September 15-19, 2025, to emphasize the importance of safety near rail crossings and the dangers of trespassing on railway property [1][3]. Group 1: Campaign Activities - Uniformed CN Police officers will be available for interviews and will participate in community events throughout the campaign week [2]. - CN is partnering with Operation Lifesaver and local authorities to deliver various online and in-person activities aimed at promoting safe practices and raising awareness about rail crossing safety [4]. Group 2: Safety Importance - Preventable accidents occur annually at rail crossings, and CN emphasizes that safety is a shared responsibility among schools, communities, and media partners [3]. - CN Police Services respond to hundreds of events across Canada and the U.S., focusing on protecting CN property and delivering rail safety presentations to various organizations [5]. Group 3: Commitment to Safety - CN continues to invest in rail safety initiatives and encourages community participation in See Tracks? Think Train® Week activities [4]. - The goal of CN Police Services is to promote safe behaviors and increase awareness of rail safety, aiming to make CN the safest railroad in North America [5].